Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire of infliximab originator, adalimumab, infliximab biosimilar, golimumab and vedolizumab have been approved in Italy.We compared the efficacy of these four biologics in UC according to the concept of continuous clinical remission (CCR).
Continuos clinical remission with biologics in Ulcerative Colitis: the A.U.R.O.R.A. comparative study
Ricci C;
2022-01-01
Abstract
Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire of infliximab originator, adalimumab, infliximab biosimilar, golimumab and vedolizumab have been approved in Italy.We compared the efficacy of these four biologics in UC according to the concept of continuous clinical remission (CCR).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Continuous_clinical_remission_with_biologics_in.6.pdf
accesso aperto
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
350.44 kB
Formato
Adobe PDF
|
350.44 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
